PeriPharm
14
0
0
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
21.4%
3 terminated/withdrawn out of 14 trials
70.0%
-16.5% vs industry average
7%
1 trials in Phase 3/4
0%
0 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
Societal Burden Associated With Type 1 Diabetes in Canada
Role: lead
Real-World Observational Study on Patient-Reported Outcomes in the Treatment of Insomnia With Daridorexant in Canada
Role: lead
The Burden of Lupus in Canada From a Patient Perspective: A Canadian Real-World PROxy Study
Role: lead
Real-World Study on the Impact of Atopic Dermatitis From a Caregiver Perspective
Role: lead
Real-World Study on the Burden of Hidradenitis Suppurativa
Role: lead
Multidimensional Burden of Platinum Resistant Ovarian Cancer (PROC) on Patients and Caregivers in Canada
Role: lead
The Burden of Multiple Myeloma on Patients and Caregivers Quality of Life: a Canadian Real-World Study
Role: lead
The Impact of Migraine on Canadians' Productivity: A Real-World Pharmacy-Based Study
Role: lead
Economic Impact of Dropless Therapy Versus Usual Care for Cataract Surgery: A Real-World Study.
Role: lead
Study to Evaluate Real-world Pharmacoeconomics of Crizotinib in NSCLC Patients
Role: lead
Real-World Outcome Research Study on Quality of Life, Work Productivity and Health Care Resource Utilization in Metastatic Breast Cancer
Role: lead
Study to Evaluate Real-world Pharmacoeconomics of Panitumumab in Metastatic Colorectal Cancer Patients
Role: lead
Study to Evaluate Real-world Pharmacoeconomics and Resistance Mechanisms of Panitumumab in Metastatic Colorectal Cancer Patients
Role: lead
Study to Evaluate Resistance Mechanisms and Real-world Pharmacoeconomics of Crizotinib in NSCLC Patients
Role: collaborator
All 14 trials loaded